Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173365 | PMC |
| http://dx.doi.org/10.18632/oncotarget.26090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving Affinity while Reducing Kidney Uptake of CXCR4-Targeting Radioligands Derived from the Endogenous Antagonist EPI-X4.
ChemMedChem
January 2025
Universitatsspital Basel, Radiopharmazeutische Chemie, Petersgraben 4, 4031, Basel, SWITZERLAND.
The C-X-C chemokine receptor 4 (CXCR4) is highly upregulated in most cancers, making it an ideal target for delivering radiation therapy to tumors. We previously demonstrated the feasibility of targeting CXCR4 in vivo using a radiolabeled derivative of EPI-X4, an endogenous CXCR4 antagonist, named DOTA-K-JM#173. However, this derivative showed undesirable accumulation in the kidneys, which would limit its clinical use.
View Article and Find Full Text PDFMSA clustering enhances AF-Multimer's ability to predict conformational landscapes of protein-protein interactions.
Bioinform Adv
December 2024
Laboratory of Experimental Biophysics, Center for Advanced Technologies, Tashkent, 100174, Uzbekistan.
Motivation: Understanding the conformational landscape of protein-ligand interactions is critical for elucidating the binding mechanisms that govern these interactions. Traditional methods like molecular dynamics (MD) simulations are computationally intensive, leading to a demand for more efficient approaches. This study explores how multiple sequence alignment (MSA) clustering enhance AF-Multimer's ability to predict conformational landscapes, particularly for proteins with multiple conformational states.
View Article and Find Full Text PDFRADIOPHARMACEUTICALS BASED ON ANTAGONISTS OF CHEMOCINE RECEPTOR CXCR4 IN DIAGNOSTICS AND TREATMENT OF ONCOLOGICAL DISEASES.
Probl Radiac Med Radiobiol
December 2024
Nonprofit Organization «National Cancer Institute of Ministry of Health of Ukraine», 33/43 Julia Zdanovska Str., Kyiv, 03022, Ukraine.
The review is devoted to the use of a new class of radiopharmaceuticals (RPs) - chemokine receptor ligands - in oncological practice. The chemokine receptor CXCR4 is of particular interest as a molecular target in the diagnosis and treatment of malignant tumors, as it plays an important role in carcinogenesis. By interacting with the chemokine CCXL12, it activates cell signaling pathways that affect tumor cell proliferation, angiogenesis, metastasis growth, and apoptosis inhibition.
View Article and Find Full Text PDFEssential strategies for the detection of constitutive and ligand-dependent Gi-directed activity of 7TM receptors using bioluminescence resonance energy transfer.
bioRxiv
December 2024
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
The constitutive (ligand-independent) signaling of G protein-coupled receptors (GPCRs) is being increasingly appreciated as an integral aspect of their function; however, it can be technically hard to detect for poorly characterized, e.g. orphan, receptors of the cAMP-inhibitory Gi-coupled (GiPCR) family.
View Article and Find Full Text PDFAgarwood as a potential therapeutic for Alzheimer's disease: Mechanistic insights and target identification.
Drug Discov Ther
January 2025
Department of Neurosurgery, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairments. Despite extensive research, its pathogenesis remains incompletely understood, and effective treatments are limited. This study explored the therapeutic potential of agarwood in AD by integrating network pharmacology, protein-protein interaction (PPI) network analysis, and single-cell expression analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!